Underdiagnosed. Under‑represented. Underwhelming outcomes. We know that there is much work to be done to bridge the PCI inequality gap between females and males. That’s why we’re committing our expertise, clinical focus and technological advances to do everything we can to narrow the gap.Read the press release
Early retrospective analyses have suggested that coronary IVL can potentially bridge the disparity in clinical outcomes between sexes, however the studies only included a limited number of females with strict inclusion criteria. Information that will be gathered in EMPOWER CAD will be immensely valuable, as it will provide more robust data with longer-term outcomes in a larger, all-comers patient cohort to determine whether coronary IVL should be considered the front-line calcium modification approach in female patients.
Professor of Medicine, Section of Cardiovascular Medicine and Director, Heart and Vascular Clinical Research Program at Yale University School of Medicine
When it comes to coronary artery disease (CAD), females are often under investigated, under treated and have less favorable outcomes than males due to a variety of different factors. Previous reports with atherectomy have shown that females with calcified CAD are more susceptible to adverse procedural outcomes compared to males. Despite often being more challenging to treat, female patients are under-represented in published data, and there have been no dedicated prospective studies performed on this population. EMPOWER CAD will be an extremely valuable study to better inform interventional cardiologists on the optimal treatment strategy for these complex patients.
Director of Complex Percutaneous Coronary Intervention Program at Columbia University Medical Center/New York‑Presbyterian Hospital
Pooled Analysis of Disrupt CAD OCT Sub-studies
The largest sex-specific OCT analysis demonstrates excellent stent expansion and MSA post-IVL with impressive procedural safety in both women and men.
Patient-level Pooled Analysis of Disrupt CAD Studies
The long-term analysis of coronary IVL finds sustained positive clinical outcomes with excellent safety in both women and men at one year.
How It Started vs. How It’s Going: Coronary Calcium Modification Outcomes in Men vs. Women
Some of us know the data. Some don’t. The question once you do is where we go from here to bridge the inequality gap between females and males? To help address this question, here is a great discussion hosted by SCAI Conversations in Interventional Cardiology with Drs. Alexandra Lansky, J. Dawn Abbott, Jennifer Tremmel, Roxana Mehran, and Suzanne Baron on the recently JSCAI published “Expert Consensus on Sex Specific Considerations in Myocardial Revascularization.”
JSCAI recently published new guidelines, which highlight disparities between females and males in coronary disease, guides future research priorities and suggests IVL as a potential first-line therapy in females with calcified lesions.Learn more
The SCAI-WIN mission is to foster professional development, education, collaboration, and research by and on behalf of women in interventional cardiology and their patients.
The Women As One mission is to promote talent in medicine, providing women physicians with unique professional opportunities. By doing this, Women As One aims to build a more inclusive, diverse and just workforce in medicine.
The Lancet Women in Cardiovascular Disease Commission, led by Dr. Roxana Mehran, summarizes existing evidence and identifies knowledge gaps in research, prevention, treatment, and access to care for women. It furthermore outlines ambitious new recommendations with a clear focus on reducing the global burden of cardiovascular disease in women by 2030.